Editors:
Addresses a gap left by the latest dyslipidemia management guidelines
Current and comprehensive discussion of options for combination therapy of dyslipidemia
Contributions from an internationally acclaimed panel of expert lipidologists
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (17 chapters)
-
Front Matter
About this book
Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation.
Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia.
Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
Keywords
- Alirocumab
- Anacetrapib
- Apolipoprotein B-100 inhibitors
- Bile acid sequestrants
- Bococizumab
- CETP inhibitors
- Cholesteryl ester transfer protein inhibitors
- Evacetrapib
- Evolocumab
- Ezetimibe
- Fibrates
- Fibric acid derivatives
- Fish oils
- Garlic
- HMG CoA reductase inhibitors
- Lomitapide
- MTP inhibitors
- Microsomal triglyceride transfer protein inhibitors
- Mipomersen
- NPC1L1 protein inhibitors
Editors and Affiliations
-
Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland
Maciej Banach
Bibliographic Information
Book Title: Combination Therapy In Dyslipidemia
Editors: Maciej Banach
DOI: https://doi.org/10.1007/978-3-319-20433-8
Publisher: Adis Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer International Publishing Switzerland 2015
Hardcover ISBN: 978-3-319-20432-1Published: 10 July 2015
Softcover ISBN: 978-3-319-36721-7Published: 15 October 2016
eBook ISBN: 978-3-319-20433-8Published: 31 July 2015
Edition Number: 1
Number of Pages: VIII, 205
Number of Illustrations: 7 b/w illustrations, 15 illustrations in colour
Topics: Cardiology, Pharmacotherapy, Pharmacology/Toxicology